Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001213900-26-030629
Filing Date
2026-03-18
Accepted
2026-03-18 15:56:31
Documents
1
Period of Report
2026-03-18

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 5738
  Complete submission text file 0001213900-26-030629.txt   7284
Mailing Address C/O IMUNON, INC. 997 LENOX DRIVE, SUITE 100 LAWRENCEVILLE NJ 08648
Business Address
Pellizzari Christine A (Reporting) CIK: 0001127430 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41084 | Film No.: 26768606

Mailing Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562
Business Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 972-9-9531142
NeuroSense Therapeutics Ltd. (Issuer) CIK: 0001875091 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)